Table 5.
Results of Cox regression multivariate analysis of progression-free survival
| Independent variable | B | SE | Z | P | HR (95%CI) |
| Gender | 0.132 | 0.433 | 0.304 | 0.761 | 1.14 (0.49-2.67) |
| Hyperbilirubinemia | 0.137 | 0.719 | 0.190 | 0.849 | 1.15 (0.28-4.69) |
| Complication | -0.581 | 0.537 | -1.082 | 0.279 | 0.56 (0.20-1.60) |
| Metastasis | 0.064 | 0.550 | 0.117 | 0.907 | 1.07 (0.36-3.13) |
| Regimen | |||||
| CPT-11 | Ref. | ||||
| FOLFIR1 | -1.238 | 0.689 | -1.796 | 0.073 | 0.29 (0.08-1.12) |
| XELIRI | -0.599 | 0.671 | -0.893 | 0.372 | 0.55 (0.15-2.05) |
| Age | -0.576 | 0.468 | -1.232 | 0.218 | 0.56 (0.22-1.41) |
| UGT1A1*6 | 0.209 | 0.514 | 0.408 | 0.683 | 1.23 (0.45-3.37) |
| UGT1A1*28 | 0.724 | 0.521 | 1.391 | 0.164 | 2.06 (0.74-5.72) |
| First-line | 1.118 | 0.657 | 1.702 | 0.089 | 3.06 (0.84-11.80) |
| ≥Second-line | 1.665 | 1.299 | 1.282 | 0.200 | 5.29 (0.41-67.70) |
| Dose decrease | -0.556 | 0.629 | -0.884 | 0.377 | 0.57 (0.17-1.97) |